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L E T T E R  T O  T H E  E D I T O R
Intravenous immunoglobulin treatment in a type 3 von 
Willebrand disease patient with alloantibodies and a  
life‐threatening gastrointestinal bleed
Dear	Editor,
Alloantibody	development	against	von	Willebrand	 factor	 (VWF)	 is	
a	 rare	 treatment	 complication	 in	 von	Willebrand	 disease	 (VWD).	
Alloantibodies	have	been	encountered	mainly	in	type	3,	the	most	se-
vere	form	with	absent	VWF,	and	particularly	in	null	mutation	cases.1 










Our	 patient	 had	 extended	 mucocutaneous	 bleeds	 postnatally	
and	was	diagnosed	at	the	time	in	the	1960s	with	‘vascular	haemo-











years	 later,	 the	 next	 delivery	 was	 handled	 with	 plasma‐derived	
VWF/FVIII	concentrate	(pdVWF/FVIII,	2.4:1	ratio,	Haemate®,	CSL	


























At	 the	age	of	49,	 a	 control	 colonoscopy	was	performed	 in	our	
hospital,	leading	to	the	severe	bleeding	episode	reported	here.	The	
procedure	 was	 decided	 to	 be	 managed	 with	 a	 different	 pdVWF/




were	 resected	 with	 satisfactory	 primary	 haemostasis.	 Wilate®	
(20	 IU/kg)	 replacement	 therapy	 was	 continued	 twice	 daily	 for	 2	










On day 7,	 the	 response	 to	 therapy	was	suddenly	 lost	 (no	mea-
surable	VWF	or	FVIII,	Figure	1).	At	the	same	time,	the	GI	bleeding	
worsened,	with	 severe	melaena	10	 times	 and	1700	mL	daily.	 This	
was	considered	to	represent	the	appearance	of	a	VWF	inhibitor,	and	
the	 patient	 was	 transferred	 to	 the	 intensive	 care	 unit.	 Treatment	
with	 rFVIIa	 (NovoSeven®,	 Novo	 Nordisk,	 at	 9.6	 mg	 [109	 µg/kg])	
every	 2	 hours	 was	 initiated	 to	 replace	Wilate®.	 To	 achieve	 local	
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therapy	 of	Haemate®	 (increasing	 doses	 from	 27/11	 to	 81/33	 IU/
kg)	and	Amofil®	(33	IU/kg)	was	initiated,	with	the	experience	that	







On day 10,	 a	 new	 control	 colonoscopy	 was	 performed,	 and	 a	
single	 active	 site	 was	 clipped.	 However,	 haemoglobin	 levels	 were	
not	 maintained,	 and	 on	 day 11,	 without	 measurable	 response	 to	
VWF	or	FVIII,	we	infused	IVIG	at	1g/kg	(90	g,	Nanogam®,	Sanquin).	







Although	 the	GI	 bleed	 stopped,	 hospitalization	was	 prolonged	
due	to	epistaxis	occurring	on	day 13,	which	was	treated	by	poste-
rior	 tamponation.	 The	 epistaxis	 recurred	 after	 the	 removal	 of	 the	




The	 bleeding	 episode	 demonstrated	 a	 classical	 outcome	 of	
an	 anti‐VWF	 antibody	 upon	 re‐exposure	 to	 a	 VWF	 concentrate,	
with	the	neutralizing	antibody	developing	at	6	days	after	 initiating	
the	 treatment.	 In	 a	 sample	 obtained	 a	 few	weeks	 after	 the	 acute	
bleeding	episode,	no	VWF	antibody	could	be	 traced	 (ELISA‐based	





and	 Inhibitor	 Prospective	 (3WINTERS‐IPS)	 study,	 still	 some	 years	







ment	 as	 part	 of	 immunotolerance	 induction	 regimens	 in	 paediat-
ric	type	3	VWD	patients,	including	the	use	of	IVIG,	rituximab	and	
mycophenolate	mofetil.5,6	However,	 according	 to	our	 knowledge,	
our	case	report	describes	for	the	first	time,	how	IVIG	therapy	pre-
ceding	 pdVWF/FVIII	 infusion	 helped	 to	 resolve	 an	 acute	 bleed	
in	 a	 type	 3	 VWD	 patient	 with	 anti‐VWF	 antibodies.	 Similar	 ap-
proach	 has	 been	 reported	 in	AVWS	mainly	 in	 cases	 of	monoclo-
nal	 gammopathy,	whereas	 our	 patient	 had	 normal	 serum	 protein	
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To	date,	 recommendations	 on	 the	 treatment	 of	VWD	patients	
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